Answers are grounded in this paper and cite their sources.
Seven-arm chaperone: A modest μM inhibitor of glucosylceramide β-glucosidase (GCase) has been transformed into a potent low-nM inhibitor by multivalency. This iminosugar inhibitor acts as a pharmacological chaperone and increases residual GCase activity in fibroblasts from Gaucher patients. These results open the way to a new class of chaperones for the treatment of lysosomal diseases.
No takes yet. Share an insight, caveat, or question.
Decroocq et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: